- Inactivated Vaccines
- Attenuated Vaccines
- Toxoid Vaccines
- Subunit Vaccines
- Conjugate Vaccines
- Others
Childhood Vaccines Market size was valued at USD 50.8 billion in 2022 and is expected to reach USD 62.22 billion by 2029, at a CAGR of 8.5% during the forecast period 2023 to 2029. Increase in the awareness regarding vaccination of various diseases in developed countries, initiations took by various government and non-governmental organizations such as World Health Organization (WHO), and Centre for Disease Control and Prevention (CDC), and growth in adoption of vaccines fuel the childhood vaccines market growth over the forecast period. Furthermore, government insurance and reimbursement scenario, low cost of vaccines, development of new vaccines for various diseases, and an increase in the healthcare expenditure might boost the global childhood vaccines market growth over the forecast period. However, adverse effects associated with the vaccines, stringent regulatory policies, and lack of awareness regarding the diseases and vaccination in low-income countries might hamper the growth of childhood vaccines market over the forecast period. Vaccines are the biological preparations which provide the active acquired immunity to the particular disease. Generally, the vaccines contain a substance that resembles the disease causing agent, and is prepared from killed or weakened form of microbe, its toxin or its surface proteins. Agents present in the vaccines stimulate the immune system of the body for recognition of the agent as foreign so that the body's immune system can easily recognize and destroy any of these microorganisms that it later encounters. Childhood vaccines are commonly administered to the age group of 3-8 years which may include DPT vaccine for Diphtheria, Pertussis, and Tetanus, Hepatitis, Influenza, and Measles vaccines, among others.
Global Childhood Vaccines Market Summary
Study Period
2024-2030
Base Year
2023
CAGR
8.5%
Largest Market
North-America
Fastest Growing Market
Asia Pacific
Childhood Vaccines Market Dynamics
Nowadays, the global childhood vaccines market is in the mature stage, competitors are focusing on the development of new vaccines for various diseases. Increase in the prevalence of various diseases such as measles, hepatitis, diphtheria, and among others might fuel the growth of childhood vaccines market. Acquisitions & mergers, collaborations, launch of new products, and technological developments are some of the key strategies followed by various companies for increasing their share in the global market over the forecast period. For instance, in January 2011, Sanofi Pasteur has inked a licensing deal with Germany's Organobalance that gives Sanofi access to a modified yeast strain for use in vaccines. Similarly, in October 2014, MabVax Therapeutics Holdings, Inc., announced that the FDA has granted an orphan drug designation to the Company's vaccine intended for the treatment of the childhood cancer neuroblastoma. In addition, in January 2013 GSK, Biological E partner on childhood vaccine to produce a 6-in-1 vaccine to protect against polio and 5 other diseases. The innovation of single vaccine for multiple diseases might fuel the global childhood vaccines market growth over the forecast period.
Childhood Vaccines Market Regional Analysis
North-America Got Significant Share
Geographically, the childhood vaccines market has been segmented into the following regions Viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. U.S. market is expected to dominate the North America regional revenue share over the coming years due to burgeoning awareness levels and adoption of state-of-art technologies to the production of vaccines. North America holds the largest share attributed to increase in the prevalence of various diseases such as pertussis (In 2014, according to the CDC, 28,660 cases of pertussis were reported in the U.S), measles, and hepatitis etc. In addition, increase in the R&D of vaccines, rise in the healthcare expenditure, and favourable reimbursement scenario might fuel the childhood vaccines market growth in the North America region. Europe market holds a dominant share owing to increase in the awareness of vaccination regarding various diseases. For instance, France made that vaccination is mandatory from 2018 because of children are dying of measles (according to the European Centre for Disease Prevention and Control, there were 79 cases of measles reported in France in the first two months of 2017). Increase in the healthcare expenditure and research and development activities boost the market in the Europe. Asia-Pacific is an emergent market for childhood vaccines due to increase in the birth rate, especially in India and China. Increase in adoption for vaccination, and growth in the prevalence of infectious disease might fuel the childhood vaccines market growth in Asia-Pacific over the forecast period. Due to less cost of vaccines, Latin America and the Middle East and Africa also hold a significant share in childhood vaccination market.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor's overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Global Childhood Vaccines Market Segmentation
By Vaccine Type
By Route Administration
- Oral
- Intramuscular
- Intradermal
- Subcutaneous
- Intranasal
By End User
- Hospitals
- Clinics
- Vaccination Centres
Frequently Asked Questions
Childhood Vaccines Market size was valued at USD 50.8 billion in 2022 and is expected to reach USD 62.22 billion by 2029, at a CAGR of 8.5% during the forecast period 2023 to 2029.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.
| 1. Executive Summary |
| 2. Global Childhood Vaccines Market Introduction |
| 2.1. Global Childhood Vaccines Market - Taxonomy |
| 2.2. Global Childhood Vaccines Market -Definitions |
| 2.2.1. Vaccine Type |
| 2.2.2. Application |
| 2.2.3. Application |
| 2.2.4. Composition |
| 2.2.5. End-User |
| 3. Global Childhood Vaccines Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Global Childhood Vaccines Market Dynamic Factors - Impact Analysis |
| 3.6. Global Childhood Vaccines Market - Regulations |
| 3.6.1. U.S. |
| 3.6.2. Europe |
| 3.7. Global Childhood Vaccines Market -Trends |
| 4. Global Childhood Vaccines Market Analysis, |
| 2018 - 2022 and Forecast, 2023 - 2029 |
| 4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. Global Childhood Vaccines Market, By Treatment Type, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.1. Inactivated Vaccines |
| 5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Attenuated Vaccines |
| 5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Toxoid Vaccines |
| 5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Subunit Vaccines |
| 5.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Conjugate Vaccines |
| 5.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 5.6. Others |
| 5.6.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.6.3. Market Opportunity Analysis |
| 6. Global Childhood Vaccines Market, By Application, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.1. Oral |
| 6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Intramuscular |
| 6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Intradermal |
| 6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Subcutaneous |
| 6.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 6.5. Intranasal |
| 6.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.5.3. Market Opportunity Analysis |
| 7. Global Childhood Vaccines Market, By Application, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 7.1. Diphtheria |
| 7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Pertussis |
| 7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Tetanus |
| 7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Polio |
| 7.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 7.5. Measles |
| 7.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.5.3. Market Opportunity Analysis |
| 7.6. Hepatitis-B |
| 7.6.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 7.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.6.3. Market Opportunity Analysis |
| 7.7. Others |
| 7.7.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 7.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.7.3. Market Opportunity Analysis |
| 8. Global Childhood Vaccines Market Forecast, By Composition, 2018 - 2022 and Forecast, 2023 - 2029 |
| 8.1. Mono Vaccines |
| 8.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Combination Vaccines |
| 8.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 9. Global Childhood Vaccines Market Forecast, By Distribution Channel, 2018 - 2022 and Forecast, 2023 - 2029 |
| 9.1. Hospitals |
| 9.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.1.3. Market Opportunity Analysis |
| 9.2. Clinics |
| 9.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.2.3. Market Opportunity Analysis |
| 9.3. Vaccination Centres |
| 9.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.3.3. Market Opportunity Analysis |
| 10. Global Childhood Vaccines Market Forecast, By Region, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 10.1. North America |
| 10.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 10.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 10.1.3. Market Opportunity Analysis |
| 10.2. Europe |
| 10.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 10.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 10.2.3. Market Opportunity Analysis |
| 10.3. Asia-Pacific |
| 10.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 10.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 10.3.3. Market Opportunity Analysis |
| 10.4. Latin America |
| 10.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 10.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 10.4.3. Market Opportunity Analysis |
| 10.5. Middle East and Africa |
| 10.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 10.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 10.5.3. Market Opportunity Analysis |
| 10.6. Global Childhood Vaccines Market - Opportunity Analysis Index, By Vaccine Type, By Route of Administration, By Application, By Composition, By End-User and Region, 2023 - 2029 |
| 11. North America Childhood Vaccines Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 11.1. Vaccine Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1. Inactivated Vaccines |
| 11.1.2. Attenuated Vaccines |
| 11.1.3. Toxoid Vaccines |
| 11.1.4. Subunit Vaccines |
| 11.1.5. Conjugate Vaccines |
| 11.1.6. Others |
| 11.2. Route of Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 11.2.1. Oral |
| 11.2.2. Intramuscular |
| 11.2.3. Intradermal |
| 11.2.4. Subcutaneous |
| 11.2.5. Intranasal |
| 11.3. Application Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 11.3.1. Diphtheria |
| 11.3.2. Pertussis |
| 11.3.3. Tetanus |
| 11.3.4. Polio |
| 11.3.5. Measles |
| 11.3.6. Hepatitis-B |
| 11.3.7. Others |
| 11.4. Composition Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 11.4.1. Mono Vaccines |
| 11.4.2. Combinition Vaccines |
| 11.5. End-User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 11.5.1. Hospitals |
| 11.5.2. Clinics |
| 11.5.3. Vaccination Centres |
| 11.6. Country Analysis 2016 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 11.6.1. US |
| 11.6.2. Canada |
| 11.7. North America Childhood Vaccines Market - Opportunity Analysis Index, By Vaccine Type, By Route of Administration, By Application, By Composition, By End-User and Country, 2023 - 2029 |
| 11.8. North America Childhood Vaccines Market Dynamics - Trends |
| 12. Europe Childhood Vaccines Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 12.1. Vaccine Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1. Inactivated Vaccines |
| 12.1.2. Attenuated Vaccines |
| 12.1.3. Toxoid Vaccines |
| 12.1.4. Subunit Vaccines |
| 12.1.5. Conjugate Vaccines |
| 12.1.6. Others |
| 12.2. Route of Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 12.2.1. Oral |
| 12.2.2. Intramuscular |
| 12.2.3. Intradermal |
| 12.2.4. Subcutaneous |
| 12.2.5. Intranasal |
| 12.3. Application Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 12.3.1. Diphtheria |
| 12.3.2. Pertussis |
| 12.3.3. Tetanus |
| 12.3.4. Polio |
| 12.3.5. Measles |
| 12.3.6. Hepatitis-B |
| 12.3.7. Others |
| 12.4. Composition Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 12.4.1. Mono Vaccines |
| 12.4.2. Combinition Vaccines |
| 12.5. End-User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 12.5.1. Hospitals |
| 12.5.2. Clinics |
| 12.5.3. Vaccination Centres |
| 12.6. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 12.6.1. Germany |
| 12.6.2. UK |
| 12.6.3. France |
| 12.6.4. Spain |
| 12.6.5. Italy |
| 12.6.6. Russia |
| 12.6.7. Poland |
| 12.6.8. Rest of Europe |
| 12.7. Europe Childhood Vaccines Market - Opportunity Analysis Index, By Vaccine Type, By Route of Administration, By Application, By Composition, By End-User and Country, 2023 - 2029 |
| 12.8. Europe Childhood Vaccines Market Dynamics - Trends |
| 13. Asia-Pacific Childhood Vaccines Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 13.1. Vaccine Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1. Inactivated Vaccines |
| 13.1.2. Attenuated Vaccines |
| 13.1.3. Toxoid Vaccines |
| 13.1.4. Subunit Vaccines |
| 13.1.5. Conjugate Vaccines |
| 13.1.6. Others |
| 13.2. Route of Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 13.2.1. Oral |
| 13.2.2. Intramuscular |
| 13.2.3. Intradermal |
| 13.2.4. Subcutaneous |
| 13.2.5. Intranasal |
| 13.3. Application Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 13.3.1. Diphtheria |
| 13.3.2. Pertussis |
| 13.3.3. Tetanus |
| 13.3.4. Polio |
| 13.3.5. Measles |
| 13.3.6. Hepatitis-B |
| 13.3.7. Others 13.4. Composition Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 13.4.1. Mono Vaccines |
| 13.4.2. Combinition Vaccines |
| 13.5. End-User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 13.5.1. Hospitals |
| 13.5.2. Clinics |
| 13.5.3. Vaccination Centres |
| 13.6. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 13.6.1. Japan |
| 13.6.2. China |
| 13.6.3. India |
| 13.6.4. ASEAN |
| 13.6.5. Australia & New Zealand |
| 13.6.6. Rest of Asia-Pacific |
| 13.7. Asia-Pacific Childhood Vaccines Market - Opportunity Analysis Index, By Vaccine Type, By Route of Administration, By Application, By Composition, By End-User and Country, 2023 - 2029 |
| 13.8. Asia-Pacific Childhood Vaccines Market Dynamics - Trends |
| 14. Latin America Childhood Vaccines Market Analysis, 2012 - 2012 - 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 14.1. Vaccine Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 14.1.1. Inactivated Vaccines |
| 14.1.2. Attenuated Vaccines |
| 14.1.3. Toxoid Vaccines |
| 14.1.4. Subunit Vaccines |
| 14.1.5. Conjugate Vaccines |
| 14.1.6. Others |
| 14.2. Route of Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 14.2.1. Oral |
| 14.2.2. Intramuscular |
| 14.2.3. Intradermal |
| 14.2.4. Subcutaneous |
| 14.2.5. Intranasal |
| 14.3. Application Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 14.3.1. Diphtheria |
| 14.3.2. Pertussis |
| 14.3.3. Tetanus |
| 14.3.4. Polio |
| 14.3.5. Measles |
| 14.3.6. Hepatitis-B |
| 14.3.7. Others |
| 14.4. Composition Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 14.4.1. Mono Vaccines |
| 14.4.2. Combinition Vaccines |
| 14.5. End-User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 14.5.1. Hospitals |
| 14.5.2. Clinics |
| 14.5.3. Vaccination Centres |
| 14.6. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 14.6.1. Brazil |
| 14.6.2. Mexico |
| 14.6.3. Argentina |
| 14.6.4. Venezuela |
| 14.6.5. Rest of Latin America |
| 14.7. Latin America Childhood Vaccines Market - Opportunity Analysis Index, By Vaccine Type, By Route of Administration, By Application, By Composition, By End-User and Country, 2023 - 2029 |
| 14.8. Latin America Childhood Vaccines Market Dynamics - Trends |
| 15. Middle East and Africa Childhood Vaccines Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 15.1. Vaccine Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 15.1.1. Inactivated Vaccines |
| 15.1.2. Attenuated Vaccines |
| 15.1.3. Toxoid Vaccines |
| 15.1.4. Subunit Vaccines |
| 15.1.5. Conjugate Vaccines |
| 15.1.6. Others |
| 15.2. Route of Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 15.2.1. Oral |
| 15.2.2. Intramuscular |
| 15.2.3. Intradermal |
| 15.2.4. Subcutaneous |
| 15.2.5. Intranasal |
| 15.3. Application Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 15.3.1. Diphtheria |
| 15.3.2. Pertussis |
| 15.3.3. Tetanus |
| 15.3.4. Polio |
| 15.3.5. Measles |
| 15.3.6. Hepatitis-B |
| 15.3.7. Others |
| 15.4. Composition Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 15.4.1. Mono Vaccines |
| 15.4.2. Combinition Vaccines |
| 15.5. End-User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 15.5.1. Hospitals |
| 15.5.2. Clinics |
| 15.5.3. Vaccination Centres |
| 15.6. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 15.6.1. Gulf Cooperation Council (GCC) Countries |
| 15.6.2. Israel |
| 15.6.3. South Africa |
| 15.6.4. Rest of MEA |
| 15.7. MEA Childhood Vaccines Market - Opportunity Analysis Index, By Vaccine Type, By Route of Administration, By Application, By Composition, By End-User and Country, 2023 - 2029 |
| 15.8. MEA Childhood Vaccines Market Dynamics - Trends |
| 16. Competition Landscape |
| 16.1. Strategic Dashboard of Top Market Players |
| 16.2. Company Profiles (Introduction, Financial Analysis, Treatment Type & Service Offerings, Key Developments, Strategies, and SWOT Analysis) |
| 16.2.1. AstraZeneca (UK) |
| 16.2.2. Bayer AG (Germany) |
| 16.2.3. Daiichi Sankyo Company Ltd (Japan) |
| 16.2.4. Eisai Co Ltd (Japan) |
| 16.2.5. GlaxoSmithKline Plc. (UK) |
| 16.2.6. Grupo Praxis Pharmaceutical SA (Spain) |
| 16.2.7. KaloBios Pharmaceuticals, Inc. (U.S.) |
| 16.2.8. Kancera AB (Sweden) |
| 16.2.9. Novartis AG (Switzerland) |
| 16.2.10. Laboratorio Elea S.A.C.I.F. y A (Argentina) |
| 16.2.11. Oblita Therapeutics BVBA (Belgium) |
| 16.2.12. Sanofi (France) |
| 17. Research Methodology |
| 18. Key Assumptions and Acronyms |
- AstraZeneca (U.K)
- Bayer AG (Germany)
- Daiichi Sankyo Company Ltd (Japan)
- Eisai Co Ltd (Japan)
- GlaxoSmithKline Plc. (U.K)
- Grupo Praxis Pharmaceutical SA (Spain)
- KaloBios Pharmaceuticals, Inc. (U.S.)
- Kancera AB (Sweden)
- Novartis AG (Switzerland)
- Laboratorio Elea S.A.C.I.F. y A (Argentina)
- Oblita Therapeutics BVBA (Belgium)
- Sanofi (France)